Heat, not surgery: new trial aims to cure thyroid cancer without a knife
NCT ID NCT07376837
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether radiofrequency ablation (using heat) can safely cure small, low-risk thyroid cancers without surgery. Thirty adults who decline surgery or active monitoring will receive the treatment and be followed for a year. The goal is to see if the cancer is completely gone after treatment, offering a less invasive option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Histologically confirmed papillary thyroid carcinoma (PTC) by fine-needle aspiration (FNA -Bethesda V/VI ) or core needle biopsy. * Single or multiple lesions, each 2.0 cm in maximum diameter. * Intrathyroidal tumors (i.e., no extrathyroidal extension, no clinical/radiological evidence of nodal metastases, nor distant metastases). * Lesions located at a safe distance (\>2 mm) from critical structures (e.g., trachea, esophagus, carotid artery) or accessible with hydrodissection. * ≤T1b (i.e. \< 2cm maximal diameter), N0 or Nx, M0 (no clinical or radiological evidence of lymph node or distant metastasis). * Patients unfit for surgery due to comorbidities or who refuse surgery. * ≥18 years old * Not pregnant at the time of RFA. * Able to understand and voluntarily sign informed consent. Exclusion Criteria: * Evidence of lymph node involvement (clinically or radiologically suspicious or confirmed metastatic nodes) or distant metastasis (e.g., lung, bone). * Tumors with extrathyroidal extension * Tumors with extensive calcification * Tumors located within 2 mm of critical structures where RFA would pose an unacceptably high risk and where hydrodissection is not feasible. * Previous thyroid surgery or ablation (RFA, ethanol, laser, or microwave) at the index tumor site. * Known diagnosis of anaplastic, poorly differentiated, or other aggressive thyroid cancer variants. * Pregnant or breastfeeding at the time of enrollment. * Bleeding diathesis or use of anticoagulants that cannot be discontinued safely prior to RFA. * Severe comorbid illness that limits life expectancy to less than 5 years. * Inability to adhere to study follow-up schedule or procedures or lacking decision-making capacity. * Implanted electrical devices such as pacemakers or neurostimulators * Infection in the neck including skin infection or thyroiditis at time of planned ablation. * Severe cervical anatomy distortion (prior neck surgery or radiation with distorted anatomy that prevents safe RFA
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thyroid papillary carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Health Network - Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.